If you or a patient is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal bloating, delayed gastric emptying—gastroparesis—may be a concern. Decades of pharmacovigilance have established that drug-induced gastrointestinal side effects require careful documentation and risk assessment. This page outlines the clinical questions and monitoring strategies for patients at higher risk.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes and for weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In placebo-controlled studies, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo: 15.3% for placebo, 32.7% for Ozempic 0.5 mg, and 36.4% for Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical presentation often includes postprandial fullness and vomiting of undigested food. Diagnosis is typically confirmed through gastric emptying scintigraphy. The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action as a GLP-1 receptor agonist, which slows gastric motility and delays gastric emptying as part of its therapeutic effect on appetite and glucose regulation. This pharmacological effect can, in susceptible individuals, progress to clinically significant gastroparesis. The label for Ozempic lists gastrointestinal adverse reactions with a frequency of less than 5%, including dyspepsia (1.9% for placebo, 3.5% for 0.5 mg, 2.7% for 1 mg), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed as a separate adverse reaction in these tables, the constellation of symptoms and the known effect on gastric emptying support a plausible link.
From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a central consideration. The label does not specifically mention gastroparesis as a warning or caution, though it does include a section on hypersensitivity reactions, noting that serious hypersensitivity reactions such as anaphylaxis and angioedema have been reported (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The absence of a specific warning for gastroparesis may affect settlement-related considerations for affected patients. Settlement criteria in litigation often hinge on whether the manufacturer provided adequate warnings about known risks. Given that gastrointestinal adverse reactions are well-documented and that delayed gastric emptying is a known pharmacological effect, plaintiffs may argue that the risk of gastroparesis should have been more prominently disclosed. The timeline between exposure and documented harm is also relevant; gastrointestinal symptoms often emerge during dose escalation, as noted in clinical trials, but progression to gastroparesis may require longer exposure or occur in individuals with predisposing factors such as diabetes, which itself is a risk factor for gastroparesis. For affected patients, settlement considerations include the severity and duration of symptoms, the need for medical interventions such as hospitalization or nutritional support, and any permanent impairment. The evidence from clinical trials indicates that gastrointestinal adverse reactions led to discontinuation in a small but notable percentage of patients (3.1% for 0.5 mg and 3.8% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In cases where gastroparesis is diagnosed, the harm may be substantial, requiring ongoing management and impacting quality of life. The mechanistic link between Ozempic and gastroparesis, combined with the documented frequency of gastrointestinal adverse reactions, provides a basis for claims that the drug contributed to the condition. However, establishing causation requires careful evaluation of individual patient history, including the timing of symptom onset relative to drug initiation and the exclusion of other causes. In summary, the evidence supports a plausible association between Ozempic use and gastroparesis, grounded in the drug's pharmacological effects and the high incidence of gastrointestinal adverse reactions in clinical trials. The adequacy of warnings is a key issue in litigation, as the label does not specifically address gastroparesis. Settlement criteria for affected patients will likely consider the strength of the causal link, the severity of harm, and the timeline of exposure. Further research and regulatory review may clarify the risk profile, but current data underscore the need for vigilance in monitoring gastrointestinal symptoms in patients using Ozempic.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
The Ozempic gastroparesis settlement refers to legal claims against the manufacturer of Ozempic (semaglutide) alleging that the drug caused gastroparesis (delayed gastric emptying) and that the company failed to adequately warn about this risk. Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis, and evidence of harm.
Eligibility generally includes: (1) documented use of Ozempic, (2) a confirmed diagnosis of gastroparesis via gastric emptying scintigraphy or other objective testing, (3) onset of symptoms after starting Ozempic, and (4) exclusion of other causes. Severity of symptoms and need for medical intervention may also be considered.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.